Ozempic 'death wave' claims: separating fear from actual risk data
Quick answer
The video claims a new study links GLP-1 receptor agonists to dopamine disruption and increased depression risk, citing a single researcher's warning. Current regulatory reviews by the FDA and EMA have not established a causal link between semaglutide or liraglutide and depression or suicidality, and several large observational studies suggest the opposite association. Patients with existing mood disorders should discuss GLP-1 therapy with their prescriber, as the neuropsychiatric picture for this drug class is still being mapped in ongoing research.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @thesun actually say?
The Sun's TikTok claims a new international study found GLP-1 medications "could mess with mood-regulating hormone dopamine," potentially raising depression risk. They quote Dr. Kenneth Bloom urging prescribers to act cautiously to avoid "another tragic wave of people dying to lose weight." That framing is dramatic, and it deserves scrutiny.
The video leans heavily on a single researcher's warning, attaches celebrity names to establish the drugs' popularity, and presents a speculative mechanism as something close to confirmed. The dopamine angle is real enough to take seriously. The way it's packaged here is not straightforward reporting.
Does the science back this up?
There is genuine ongoing research into GLP-1 receptors and dopamine pathways, but the evidence for a depression risk is preliminary and contested. Studies showing benefit actually outnumber those showing harm at this point.
GLP-1 receptors are expressed in the brain's mesolimbic system, which governs reward and mood. A 2023 study by Wium-Andersen et al. in JAMA Network Open found semaglutide was associated with a reduced risk of new-onset depression and suicidal ideation in large insurance claims data. Separately, the European Medicines Agency reviewed suicidality signals for semaglutide and liraglutide in 2023 and found no established causal link. The FDA issued a similar finding. The Bloom study referenced in the video has not been independently verified in this fact-check as published in a peer-reviewed journal, and citing a researcher from "Ariel University in California" raises a flag: Ariel University is in Israel, not California.
What did they get wrong (or right)?
They got the dopamine mechanism partially right as a concept worth watching, but they got several things wrong in execution.
- The attribution error is significant. Dr. Kenneth Bloom's institution is listed as being in California when Ariel University is located in the West Bank, Israel. That kind of factual slip erodes trust in the sourcing overall.
- The phrase "mood-regulating hormone dopamine" is a simplification. Dopamine is a neurotransmitter, not a hormone in the classical sense, and its relationship with mood is far more complex than the video suggests.
- The framing implies a settled scientific consensus that does not exist. Calling it an "urgent warning" based on one study and one researcher is a stretch the evidence does not currently support.
- On the positive side, raising the question of CNS effects for GLP-1 drugs is legitimate. This is an active area of research and patients and prescribers should be aware these drugs do cross the blood-brain barrier.
What should you actually know?
The neurological effects of GLP-1 drugs are a real and active area of research, but the current evidence tilts toward mood benefit rather than harm in most published studies. That picture could change.
The FDA and EMA have both reviewed suicide and depression signals for semaglutide and found no confirmed causal link, though monitoring continues. A 2024 study by Norgaard et al. in Nature Medicine using Danish registry data found GLP-1 users had lower rates of depression diagnoses compared to matched controls. If you are already being treated for a mood disorder and are considering a GLP-1 medication, that is absolutely a conversation to have with your prescriber. Not because this video proved a risk, but because your full medical history should always be part of that decision. One alarming TikTok is not a clinical consultation.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic 'death wave' claims: separating fear from actual risk data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video claims a new study links GLP-1 receptor agonists to dopamine disruption and increased depression risk, citing a single researcher's warning.
FormBlends verdict
The video claims a new study links GLP-1 receptor agonists to dopamine disruption and increased depression risk, citing a single researcher's warning. Current regulatory reviews by the FDA and EMA have not established a causal link between semaglutide or liraglutide and depression or suicidality, and several large observational studies suggest the opposite association. Patients with existing mood disorders should discuss GLP-1 therapy with their prescriber, as the neuropsychiatric picture for this drug class is still being mapped in ongoing research.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video claims a new study links GLP-1 receptor agonists to dopamine disruption and increased depression risk, citing a single researcher's warning. Current regulatory reviews by the FDA and EMA have not established a causal link between semaglutide or liraglutide and depression or suicidality, and several large observational studies suggest the opposite association. Patients with existing mood disorders should discuss GLP-1 therapy with their prescriber, as the neuropsychiatric picture for this drug class is still being mapped in ongoing research.
- The FDA and EMA both reviewed suicidality and depression signals for semaglutide in 2023 and found no confirmed causal relationship.
- A 2023 JAMA Network Open study by Wium-Andersen et al. found semaglutide associated with lower, not higher, rates of new-onset depression in insurance claims data.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- The FDA and EMA both reviewed suicidality and depression signals for semaglutide in 2023 and found no confirmed causal relationship.
- A 2023 JAMA Network Open study by Wium-Andersen et al. found semaglutide associated with lower, not higher, rates of new-onset depression in insurance claims data.
- GLP-1 receptors do exist in the brain's reward system, so neuropsychiatric research is scientifically legitimate, but the current published data does not support a depression risk claim.
- Ariel University is in Israel, not California as stated in the video. That geographic error is a red flag about how carefully the source was checked.
- Dopamine is a neurotransmitter, not a hormone. The distinction matters because the mechanisms of action and drug interactions differ significantly.
- A 2024 Nature Medicine study by Norgaard et al. using Danish national registry data found GLP-1 users had lower rates of depression diagnoses compared to matched non-users.
- If you have a history of depression or mood disorders, discuss that with a prescriber before starting any GLP-1 medication, not because this video proved a risk, but because your full history always belongs in that conversation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
The Sun · TikTok creator
1.6M views on this video
Click to read the full story. Urgent warning over new ‘Ozempic’ side effect as scientists fear ‘tragic wave of people dying to lose weight’. #weightloss #ozempic #health
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by The Sun, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.